Axa acquired a new position in Intercept Pharmaceuticals Inc (NASDAQ:ICPT) in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 29,755 shares of the biopharmaceutical company’s stock, valued at approximately $3,760,000. Axa owned 0.10% of Intercept Pharmaceuticals as of its most recent filing with the Securities & Exchange Commission.
Other institutional investors have also modified their holdings of the company. Strs Ohio purchased a new position in Intercept Pharmaceuticals in the third quarter worth approximately $126,000. Chicago Equity Partners LLC purchased a new position in Intercept Pharmaceuticals in the third quarter worth approximately $215,000. GWM Advisors LLC purchased a new position in Intercept Pharmaceuticals in the third quarter worth approximately $220,000. Tocqueville Asset Management L.P. acquired a new position in Intercept Pharmaceuticals during the second quarter worth $252,000. Finally, United Services Automobile Association acquired a new position in Intercept Pharmaceuticals during the second quarter worth $280,000. Institutional investors own 63.20% of the company’s stock.
A number of research analysts have commented on ICPT shares. Zacks Investment Research upgraded Intercept Pharmaceuticals from a “hold” rating to a “buy” rating and set a $113.00 price target on the stock in a research note on Tuesday, November 13th. Wedbush set a $220.00 price target on Intercept Pharmaceuticals and gave the stock a “buy” rating in a research note on Tuesday, November 6th. Cantor Fitzgerald restated an “overweight” rating and set a $170.00 price target on shares of Intercept Pharmaceuticals in a research note on Monday, October 1st. Roth Capital started coverage on Intercept Pharmaceuticals in a research note on Wednesday, September 12th. They set a “buy” rating and a $192.00 price target on the stock. Finally, Goldman Sachs Group upgraded Intercept Pharmaceuticals from a “sell” rating to a “buy” rating and upped their price target for the stock from $46.00 to $157.00 in a research note on Monday, August 6th. Seven research analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company. Intercept Pharmaceuticals presently has an average rating of “Buy” and a consensus price target of $148.25.
NASDAQ:ICPT opened at $110.91 on Monday. The firm has a market cap of $3.29 billion, a price-to-earnings ratio of -7.71 and a beta of -1.08. The company has a debt-to-equity ratio of 3.83, a quick ratio of 5.98 and a current ratio of 5.98. Intercept Pharmaceuticals Inc has a 52 week low of $51.05 and a 52 week high of $133.74.
Intercept Pharmaceuticals (NASDAQ:ICPT) last announced its quarterly earnings data on Wednesday, October 31st. The biopharmaceutical company reported ($2.18) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.65) by $0.47. The business had revenue of $47.00 million for the quarter, compared to analysts’ expectations of $48.24 million. Intercept Pharmaceuticals had a negative return on equity of 645.54% and a negative net margin of 202.93%. The company’s revenue for the quarter was up 13.8% compared to the same quarter last year. During the same period last year, the firm earned ($2.89) earnings per share. As a group, analysts anticipate that Intercept Pharmaceuticals Inc will post -10.35 EPS for the current fiscal year.
In other news, insider David Shapiro sold 759 shares of the stock in a transaction on Friday, October 5th. The stock was sold at an average price of $110.65, for a total value of $83,983.35. Following the sale, the insider now directly owns 39,152 shares in the company, valued at $4,332,168.80. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, EVP Christian Weyer sold 1,343 shares of the stock in a transaction on Thursday, November 29th. The shares were sold at an average price of $113.78, for a total value of $152,806.54. Following the completion of the sale, the executive vice president now owns 17,162 shares in the company, valued at $1,952,692.36. The disclosure for this sale can be found here. Over the last quarter, insiders sold 62,444 shares of company stock worth $6,383,435. Insiders own 4.90% of the company’s stock.
TRADEMARK VIOLATION NOTICE: “Axa Acquires Shares of 29,755 Intercept Pharmaceuticals Inc (ICPT)” was originally published by American Banking News and is owned by of American Banking News. If you are accessing this story on another website, it was illegally copied and republished in violation of United States and international copyright laws. The correct version of this story can be viewed at https://www.americanbankingnews.com/2018/12/03/axa-acquires-shares-of-29755-intercept-pharmaceuticals-inc-icpt.html.
Intercept Pharmaceuticals Profile
Intercept Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics in the United States, Europe, and Canada. Its lead product candidate is obeticholic acid (OCA), a bile acid analog, which has a structure based on a naturally occurring human bile acid that selectively binds to and activates the farnesoid X receptor (FXR).
Further Reading: Momentum Indicator: Relative Strength Index
Receive News & Ratings for Intercept Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.